MARKET

CERO

CERO

CERo Therapeutics
OTCMQB
0.012
-0.004
-24.05%
Closed 15:43 09/03 EDT
OPEN
0.016
PREV CLOSE
0.016
HIGH
0.016
LOW
0.012
VOLUME
862.60K
TURNOVER
11.11K
52 WEEK HIGH
895.40
52 WEEK LOW
0.0075
MARKET CAP
859.57K
P/E (TTM)
-0.0009
1D
5D
1M
3M
1Y
5Y
1D
CERo Therapeutics Holdings Secures New Consolidated Financing Facility
TipRanks · 3d ago
Weekly Report: what happened at CERO last week (0824-0828)?
Weekly Report · 3d ago
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
Barchart · 3d ago
Weekly Report: what happened at CERO last week (0817-0821)?
Weekly Report · 08/24 10:05
Weekly Report: what happened at CERO last week (0810-0814)?
Weekly Report · 08/17 10:06
CERO THERAPEUTICS HOLDINGS, INC. FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026
Press release · 08/15 07:45
Weekly Report: what happened at CERO last week (0803-0807)?
Weekly Report · 08/10 10:02
Weekly Report: what happened at CERO last week (0727-0731)?
Weekly Report · 08/03 10:01
More
About CERO
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Webull offers CERo Therapeutics Holdings Inc stock information, including OTCMQB: CERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERO stock methods without spending real money on the virtual paper trading platform.